Skip to main content

Dexcom stock price and financials

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026
Market value
$30.72B
P/E
31.00
EV / EBITDA
20.99
Beta · 1 year
0.69
Return · 1 year
+39.8%
52-week range$56.72 — $92.59

Share price close 16 Nov 2026

−6.4%1 monthHigh $88.48Low $77.94
$75$80$85$90Q3 FY2026 report filed 29 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+33.1%6 monthsHigh $92.34Low $65.09
$60$70$80$90$100Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+23.6%year to dateHigh $92.34Low $57.56
$50$60$70$80$90$100Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+41.3%1 yearHigh $92.34Low $57.56
$50$60$70$80$90$100Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
−19.6%3 yearsHigh $140.45Low $54.84
$50$75$100$125$150Q4 FY2023 report filed 8 Feb 2024Q1 FY2024 report filed 25 Apr 2024Q2 FY2024 report filed 25 Jul 2024Q3 FY2024 report filed 24 Oct 2024Q4 FY2024 report filed 18 Feb 2025Q1 FY2025 report filed 1 May 2025Q2 FY2025 report filed 30 Jul 2025Q3 FY2025 report filed 30 Oct 2025Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+360%10 yearsHigh $161.64Low $11.14
$0$50$100$150$200Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Dexcom reported revenue of $4.66 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 15.6% from fiscal 2024. Net income was $836 million and diluted earnings per share $2.09.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.34 billion, up 11.2% from a year earlier.

Figures from Dexcom's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Against Health Care

Growth
Top 10%
Revenue +19.3% a year over five years · 2nd of 37
Profitability
Top quarter
Return on invested capital 16.8%, five-year average · 9th of 38
Balance sheet
Top quarter
Net debt 0.3× EBITDA · 10th of 38
Valuation
Below the median
P/E 31.0 · 18th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$4.66B+15.6%
Net income
$836.3M+45.1%
Diluted EPS
$2.09+47.2%
Gross margin
60.1%−0.4 pts
Free cash flow
$1.08B+70.8%
Net debt
$418.2M

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$1B$0$1B$2B$3B$4B$5BRevenue, FY16: $573.3MNet income, FY16: −$65.6MFY16Revenue, FY17: $718.5MNet income, FY17: −$50.2MFY17Revenue, FY18: $1.03BNet income, FY18: −$127.1MFY18Revenue, FY19: $1.48BNet income, FY19: $101.1MFY19Revenue, FY20: $1.93BNet income, FY20: $549.7MFY20Revenue, FY21: $2.45BNet income, FY21: $216.9MFY21Revenue, FY22: $2.91BNet income, FY22: $341.2MFY22Revenue, FY23: $3.62BNet income, FY23: $541.5MFY23Revenue, FY24: $4.03BNet income, FY24: $576.2MFY24Revenue, FY25: $4.66BNet income, FY25: $836.3MFY25

Where the revenue comes from FY 2025 · $4.66B

Dexcom revenue by country, FY 2025
CountryRevenueShareChange
United States$3.33B72%+15.4%
International$1.33B28%+16.1%
Each line by fiscal year →

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 29 Oct 2026 · Full results →

Revenue
$1.34B+11.2% on a year
Gross margin
64.3%+3.8 pts on a year
Operating income
$327.2M+34.9% on a year
Net income
$275.1M−3.1% on a year
Diluted EPS
$0.72+2.9% on a year
Free cash flow
$272.7M−52.9% on a year

Comparable companies All of Health Care →

Dexcom beside the other S&P 500 members in Health Care Equipment, by market value.

Dexcom and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
DexcomDXCM$30.72B+2.4%+39.8%+13.0%19.4%31.0
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-50%0%50%100%60.1%19.6%17.9%FY16FY19FY22FY25

Dexcom revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By country

Dexcom revenue by country, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$1.85B$2.14B+15.8%$2.63B+22.6%$2.89B+10.1%$3.33B+15.4%
International$599.1M$767.8M+28.2%$997.0M+29.9%$1.14B+14.7%$1.33B+16.1%
Total revenue$2.45B$2.91B$3.62B$4.03B$4.66B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Dexcom income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$573.3M$718.5M$1.03B$1.48B$1.93B$2.45B$2.91B$3.62B$4.03B$4.66B
Revenue growth+42.6%+25.3%+43.6%+43.1%+30.5%+27.1%+18.8%+24.5%+11.3%+15.6%
Gross profit$378.4M$492.1M$663.9M$931.5M$1.28B$1.68B$1.88B$2.29B$2.44B$2.80B
Operating income−$63.90M−$42.50M−$186.3M$142.3M$299.5M$265.8M$391.2M$597.7M$600.0M$911.8M
Net income−$65.60M−$50.20M−$127.1M$101.1M$549.7M$216.9M$341.2M$541.5M$576.2M$836.3M
Diluted EPS−$0.20−$0.15−$0.36$0.27$1.33$0.53$0.82$1.30$1.42$2.09
Gross margin66.0%68.5%64.4%63.1%66.4%68.6%64.7%63.2%60.5%60.1%
Operating margin−11.1%−5.9%−18.1%9.6%15.5%10.9%13.4%16.5%14.9%19.6%
Net margin−11.4%−7.0%−12.3%6.8%28.5%8.9%11.7%14.9%14.3%17.9%

Cash flow

Dexcom cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$56.20M$92.00M$123.2M$314.5M$475.6M$442.5M$669.5M$748.5M$989.5M$1.44B
Capital expenditure$55.70M$66.00M$67.10M$180.0M$199.0M$389.2M$364.8M$236.6M$358.8M$363.5M
Free cash flow$500.0K$26.00M$56.10M$134.5M$276.6M$53.30M$304.7M$511.9M$630.7M$1.08B

Balance sheet and shares

Dexcom balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$94.50M$441.5M$1.14B$446.2M$817.6M$1.05B$642.3M$566.3M$606.1M$917.7M
Total debt$0.00$327.6M$1.01B$1.15B$1.79B$2.10B$1.31B$2.54B$1.32B$1.34B
Shareholders' equity$283.8M$419.4M$663.3M$882.6M$1.83B$2.04B$2.13B$2.07B$2.10B$2.75B
Diluted shares334M345M353M369M420M429M428M426M413M406M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Dexcom quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.11B$1.04B$1.16B$1.21B$1.26B$1.19B$1.31B$1.34B
Revenue, year on year+7.6%+12.5%+15.2%+21.6%+13.1%+15.0%+13.1%+11.2%
Gross margin58.9%56.9%59.5%60.5%62.9%62.9%63.4%64.3%
Operating income$188.9M$133.7M$212.6M$242.5M$323.0M$255.3M$318.3M$327.2M
Net income$151.7M$105.4M$179.8M$283.8M$267.3M$199.5M$249.1M$275.1M
Diluted EPS$0.37$0.27$0.45$0.70$0.67$0.51$0.64$0.72
Free cash flow$176.8M$96.80M$208.9M$579.4M$192.1M$449.0M$184.5M$272.7M

Operating KPIs

The operating figures Dexcom reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Dexcom operating KPIs
KPILatestPeriodChange on a yearRecent periods
U.S. revenue (change on a year)14%quarter to 30 Sep 2026down 7.0 points

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Dexcom's revenue in fiscal 2025?

$4.66 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Dexcom's net income in fiscal 2025?

$836 million for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Dexcom's diluted earnings per share in fiscal 2025?

$2.09 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Dexcom's gross margin?

60.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Dexcom's operating margin?

19.6% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Dexcom generate in fiscal 2025?

$1.08 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Dexcom's revenue come from?

In fiscal 2025, by country: United States $3.33B (72%), International $1.33B (28%), out of $4.66B in all, as stated in its annual report.

In the terminal

Twenty years of Dexcom's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans